Tests a ceramide nanoliposome drug in adults with returning or resistant acute myeloid leukemia

Trial details

Who runs it

Keystone Nano, Inc

Trial code

NCT04716452

Record updated

3 November 2026

Original description

The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .Read full original descriptionShow less

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)

The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .

Inclusion: Signed informed consent is obtained prior to conducting any study-specific screening procedures; Willing and able to understand the nature of this study and to comply with the study and follow-up procedures; Age and Disease: ≥ 18 years of age with refractory or relapsed AML; Refractory AML: Patients who fail to achieve a complete remission (CR) or a complete remission with incomplete count recovery (CRi) after one or more ines of AML directed therapy; Relapsed AML: Patients who achieved a complete remission (CR) or a complete remission with incomplete count recovery (CRi) with one or more prior lines of AML directed therapy but then developed a relapse of AML; Note: Patients are eligible even if they have not received intensive induction chemotherapy but have been treated with other AML directed therapy like hypomethylating agents (azacitidine, decitabine); Eastern Cooperative Oncology Group (ECOG) performance status must be ≤2; ECOG performance status must be ≤2; Peripheral white blood cell (WBC) count <30,000/µL. For cyto-reduction, the following are allowed to reduce WBC count to < 30,000/µL:; hydroxyurea is allowed during screening and through the end of Cycle,; cytarabine is allowed during screening but not after registration and should be limited 1 g/m2 or less from time of consent to registration; Adequate organ function as evidenced by the following laboratory findings:; Total bilirubin ≤ 1.5 × upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN if not attributed to leukemia, or ≤ 5 x ULN if attributed to leukemia; Creatinine clearance > 60 mL/min.

Exclusion: Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months before registration, or psychiatric illness/social situations that would limit compliance with study requirements; Patients may not be receiving any other concurrent investigational agents during study treatment and not for at least within one week prior to starting study treatment; History of any other malignancies within the preceding 12 months before registration with the exception of in-situ cancer, non-muscle invasive bladder cancer, non-metastatic prostate cancer, basal or squamous cell skin cancer; Past Hematopoietic stem cell transplant (HSCT) with graft vs host disease, immunosuppression other than low dose prednisone (10 mg) (or equivalent does of another immunosuppressant) within the 4 weeks before registration; All adverse reactions from prior therapy must have recovered to Grade ≤ 1 or acceptable baseline per treating investigator; Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the Investigator's opinion, could compromise the patient's safety or put the study outcomes at risk; Evidence of isolated extramedullary disease; Severe infection requiring treatment that would interfere with study drug(s) or study participation in the opinion of the treating investigator; Patients meeting any of the following criteria are ineligible for study entry:; Since the teratogenic potential of this combination is currently unknown, females who are pregnant or lactating are excluded; Acute Promyelocytic Leukemia; AML with active central nervous system (CNS) involvement (as determined by study investigator).

ClinicalTrials.gov NCT04716452